Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Blankenstein, Thomas Prof. Dr. (21) Daniel, Peter Prof. Dr. (1) Kammertöns, Thomas Dr. (4) Kieback, Elisa Dr. (2) Kopp, Joachim Dr. (2) Pezzutto, Antonio Prof. Dr. (2) Schlag, Peter M. Prof. Dr. (1) (-) Bunse, Mario Dr. (1) (-) Leisegang, Matthias Prof. Dr. rer. nat. (3) (-) Uckert, Wolfgang Prof. Dr. (6) (-) Willimsky, Gerald Dr. (7) Bioinformatik der Genregulation (1) Experimentelle Ultrahochfeld-MR (6) Genetik metabolischer und reproduktiver Störungen (3) Genom-Editierung & Krankheitsmodelle (2) Genomics (1) Immunregulation und Krebs (3) Magnetic Resonance (6) Mobile DNA (2) (-) Molekulare Immunologie und Gentherapie (13) Proteom Dynamik (1) RNA Biologie und Posttranscriptionale Regulation (1) Transgenics (2) Translationale Onkologie solider Tumore (1) Zelluläre Neurowissenschaften (5) 1997 (1) 1998 (1) 2000 (3) 2002 (1) 2003 (4) 2004 (1) 2005 (7) 2006 (1) 2007 (4) (-) 2008 (3) (-) 2010 (5) (-) 2011 (3) 2013 (5) 2014 (1) 2015 (2) (-) 2016 (2) 2017 (2) 2018 (5) 2019 (2) 2020 (1) 2021 (1) 2022 (3) 2023 (2) 13 Ergebnisse: Active Filter: Bunse, Mario Dr.Leisegang, Matthias Prof. Dr. rer. nat.Uckert, Wolfgang Prof. Dr.Willimsky, Gerald Dr.Molekulare Immunologie und Gentherapie 2008201020112016 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 15. März 2010 / J Immunol In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance C. Buschow J. Charo K. Anders C. Loddenkemper A. Jukica W. Alsamah C. Perez G. Willimsky T. Blankenstein 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 15. April 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 01. September 2010 / Eur J Immunol Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo S. Shalapour K. Deiser O. Sercan J. Tuckermann K. Minnich G. Willimsky T. Blankenstein G.J. Haemmerling B. Arnold T. Schueler 16. Dezember 2010 / Oncogene The immune response to sporadic colorectal cancer in a novel mouse model M. Czeh C. Loddenkemper S. Shalapour C. Schoen S. Robine E. Goldscheid H. Stein T. Schueler G. Willimsky T. Blankenstein 01. März 2016 / J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein 17. Mai 2016 / Immunity Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity E. Kieback E. Hilgenberg U. Stervbo V. Lampropoulou P. Shen M. Bunse Y. Jaimes P. Boudinot A. Radbruch U. Klemm A.A. Kühl R. Liblau N. Hoevelmeyer S.M. Anderton W. Uckert S. Fillatreau 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
15. März 2010 / J Immunol In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance C. Buschow J. Charo K. Anders C. Loddenkemper A. Jukica W. Alsamah C. Perez G. Willimsky T. Blankenstein
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
15. April 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
01. September 2010 / Eur J Immunol Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo S. Shalapour K. Deiser O. Sercan J. Tuckermann K. Minnich G. Willimsky T. Blankenstein G.J. Haemmerling B. Arnold T. Schueler
16. Dezember 2010 / Oncogene The immune response to sporadic colorectal cancer in a novel mouse model M. Czeh C. Loddenkemper S. Shalapour C. Schoen S. Robine E. Goldscheid H. Stein T. Schueler G. Willimsky T. Blankenstein
01. März 2016 / J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein
17. Mai 2016 / Immunity Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity E. Kieback E. Hilgenberg U. Stervbo V. Lampropoulou P. Shen M. Bunse Y. Jaimes P. Boudinot A. Radbruch U. Klemm A.A. Kühl R. Liblau N. Hoevelmeyer S.M. Anderton W. Uckert S. Fillatreau
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein